DTC-0220

N/A

Report date: 2024/09/26 18:01:08
NME

Base Information

Drug NameDTC-0220
Drug Alias NameDTC-0220
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase LCK inhibitorsTyrosine-protein kinase JAK2 inhibitorsABL proto-oncogene 1 inhibitors +[7] 
TargetsTyrosine-protein kinase LCKTyrosine-protein kinase JAK2ABL proto-oncogene 1 +[7] 
Therapy Area/IndicationsLung NeoplasmsOvarian NeoplasmsColonic Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesDELiver Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesDELiver Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsLung NeoplasmsOvarian NeoplasmsColonic Neoplasms +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A